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ABSTRACT
Objective: To determine the efficacy and safety of deutetrabenazine as a treatment for tardive
dyskinesia (TD).
Methods: One hundred seventeen patients with moderate to severe TD received deutetrabena-
zine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an
Abnormal Involuntary Movement Scale (AIMS) score of $6 assessed by blinded central video
rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint
was the change in AIMS score from baseline to week 12. Secondary endpoints included treat-
ment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global
Impression of Change.
Results: For the primary endpoint, deutetrabenazine significantly reduced AIMS scores from
baseline to week 12 vs placebo (least-squares mean [standard error] 23.0 [0.45] vs 21.6
[0.46], p 5 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine
but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric
adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and sui-
cidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured
by the Unified Parkinson’s Disease Rating Scale motor subscale, was noted from baseline to week
12 in either group.
Conclusions: In patients with TD, deutetrabenazine was well tolerated and significantly reduced
abnormal movements.
Classification of evidence: This study provides Class I evidence that in patients with TD, deutetra-
benazine reduces AIMS scores. Neurology® 2017;88:2003–2010
GLOSSARY
AE 5 adverse event; AIMS 5 Abnormal Involuntary Movement Scale; ARM-TD 5 Aim to Reduce Movements in Tardive
Dyskinesia; CGIC 5 Clinical Global Impression of Change; CI 5 confidence interval; DRA 5 dopamine receptor antagonist;
First-HD 5 First Time Use of SD-809 in Huntington Disease; HADS 5 Hospital Anxiety and Depression Scale; HD 5
Huntington disease; LS 5 least-squares; mCDQ-24 5 modified Craniocervical Dystonia Questionnaire; mITT 5 modified
intent-to-treat; PGIC5 Patient Global Impression of Change; QTcF5QT interval corrected with the Fridericia formula; SE5
standard error; TD 5 tardive dyskinesia; VMAT2 5 vesicular monoamine transporter 2.
Tardive dyskinesia (TD) is a movement disorder resulting from exposure to dopamine receptor
antagonists (DRAs), including typical and atypical antipsychotics, antiemetics, and metoclopra-
mide.1–3 TD can affect any part of the body and be debilitating.1,4 Approximately 20% to 50%
of patients receiving antipsychotics develop TD.5 The pathophysiology of TD is unknown, but
upregulation and sensitization of D2 receptors after prolonged blockade may be contributory.5,6
Continued DRA use may worsen symptoms,1,6 while dose reduction can increase the risk of
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psychiatric relapse or acutely worsen TD.7–10
In.80% of patients, TD appears irreversible,
even after the causative agent is discontin-
ued.11 There are currently no US Food and
Drug Administration–approved treatments
for TD.12 Although some off-label treatments
have been studied for the management of
TD,8 a significant unmet need remains for
a tolerable and efficacious treatment option
that allows the continuation of concomitant
DRA use for underlying comorbidities.
Tetrabenazine is a vesicular monoamine
transporter 2 (VMAT2) inhibitor that modu-
lates synaptic dopamine.13 Tetrabenazine is
rapidly and extensively converted in the liver
to alpha and beta active metabolites, which are
potent and selective inhibitors of VMAT2.
These active metabolites have short half-
lives that necessitate frequent dosing and result
in large plasma fluctuations that are thought
to contribute to the poor tolerability often
observed.14,15 Conventional tetrabenazine-
associated neuropsychiatric adverse events
(AEs), including somnolence, depression,
insomnia, akathisia, and parkinsonism, may
limit its use.13
Deutetrabenazine is a novel, highly selective
VMAT2 inhibitor containing deuterium, a nat-
urally occurring, nontoxic form of hydrogen.16
Incorporation of deuterium attenuates metab-
olism, leading to decreased plasma fluctuations
compared with conventional tetrabenazine,17,18
with potential to reduce AEs associated with
peak concentrations. For example, deutetrabe-
nazine significantly decreased chorea, improved
overall motor function, and was well tolerated,
with low rates of neuropsychiatric symptoms in
patients with Huntington disease (HD),19
a population with high psychiatric comorbid-
ity.20 This study evaluates the efficacy, safety,
and tolerability of deutetrabenazine for the
treatment of TD.
METHODS Primary research question. Is deutetrabena-
zine effective at reducing the severity of abnormal involuntary
movements of TD as measured using the Abnormal Involuntary
Movement Scale (AIMS) score? This study provides Class I evi-
dence that in patients with TD, deutetrabenazine reduces AIMS
scores.
Standard protocol approvals, registrations, and patient
consents. This phase II/III trial is registered at ClinicalTrials.gov
(NCT02195700). Written approval of the study protocol was
obtained from the independent ethics committee at each site.
Informed consent was secured for each patient. This study was
conducted from June 2014 to May 2015.
Patient population. Participants had a TD diagnosis for $3
months before screening and a history of DRA treatment for $3
months ($1 month if age $60 years). Patients were required to
have investigator-assessed total AIMS motor score $6 (examina-
tion of items 1–7) at both screening and baseline, verified by
a blinded central rater at screening. For logistic reasons, the video of
the AIMS motor score at baseline could not be assessed by blinded
central rating until after randomization. Psychoactive medication
use, including antipsychotics, was allowed if stable for $30 days
before screening (antidepressants $45 days).
Treatment with tetrabenazine, reserpine, a-methyl-p-tyro-
sine, strong anticholinergic medications, metoclopramide, dopa-
mine agonists, levodopa, and/or stimulants within 30 days of
screening or baseline was exclusionary, as was treatment with
botulinum toxin within 3 months of screening. Other exclusions
included presence of a neurologic condition that could confound
TD assessments, serious untreated or undertreated psychiatric
illness, or unstable medical illness. Patients with history of or
active suicidal ideation or behavior within 6 months of screening
or score $11 on the depression subscale of the Hospital Anxiety
and Depression Scale (HADS) were excluded. A corrected QT
interval with the Fridericia formula (QTcF) of.450 milliseconds
in men or .460 milliseconds in women on 12-lead ECG at
screening was also exclusionary.
Study design. This was a 12-week, randomized, double-blind,
parallel-group study conducted at 46 sites in the United States
and Europe. Patients were centrally randomized 1:1 to receive
deutetrabenazine or matching placebo and stratified by use of
DRA at baseline (currently taking vs not currently taking a DRA).
Randomization and stratification were performed through an
Interactive Technology Response System. Both patients and site
investigators remained blinded to treatment assignment
throughout the study.
After randomization, study drug was started at 12 mg/d (6 mg
twice daily) and titrated weekly by 6 mg/d, if required, for up to 6
weeks until adequate dyskinesia control was achieved, a significant
AE occurred, or the maximal allowable dose (48 mg/d) was
reached; this was followed by maintenance (6 weeks) and a 1-
week washout. The investigator, in consultation with the patient
and caregiver (if applicable), determined the optimal dose for dys-
kinesia control. In patients receiving a strong CYP2D6 inhibitor,
the maximum allowed dose of deutetrabenazine was 36 mg/d.
Clinic visits and AIMS evaluations were performed at weeks 2, 4,
6, 9, 12, and 13. Telephone consultations occurred at weeks 1, 3,
5, and 7.
Efficacy assessments. The primary endpoint was change in
AIMS score from baseline to week 12 as assessed by 2 blinded
central video raters who were movement disorders experts. For
each of the 7 body regions, a consensus AIMS rating was reached.
Video recordings were blinded with respect to treatment, visit
number, investigation site, and recording date. All videos for a sin-
gle patient were reviewed by both raters in a single session.
Secondary endpoints included proportion of patients who
experienced treatment success at week 12 on the Clinical Global
Impression of Change (CGIC) and Patient Global Impression of
Change (PGIC), 7-point Likert scales ranging from very much
worse to very much improved. CGIC assessment occurred at
weeks 2, 4, 6, 9, and 12. PGIC assessment occurred weeks 4,
6, 9, and 12. Treatment success on the CGIC and PGIC was
defined as much improved or very much improved at week 12.
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The change from baseline in modified Craniocervical Dystonia
Questionnaire (mCDQ-24) score was also measured. The
mCDQ-24 contains domains that are relevant to TD, such as
stigma, emotional well-being, pain, activities of daily living, and
social/family life, thereby enabling the evaluation of the effect
and significance of TD on patients’ quality of life.
Because the baseline visit video could not be assessed by cen-
tral raters before randomization, some of the enrolled patients had
an AIMS motor score ,6 when assessed by the central raters;
these patients were enrolled in the study on the basis of an AIMS
score of $6 at baseline, as assessed by the local site rater. There-
fore, a post hoc analysis of patients with centrally read AIMS
motor scores $6 at both screening and baseline was performed.
Other efficacy endpoints such as CGIC, PGIC, and mCDQ-24
were also analyzed.
Safety assessments. AEs were monitored throughout the study
and are reported after randomization. Dose reductions, suspen-
sions, and withdrawals due to AEs were also monitored. ECG
readings were measured at baseline and weeks 2 and 12; addi-
tional readings occurred at weeks 4, 6, and 9 for patients receiving
medications that potentially prolong the QT interval. Assessment
of Unified Parkinson’s Disease Rating Scale motor subscale,
Barnes Akathisia Rating Scale, HADS, Columbia Suicide Severity
Rating Scale, and Epworth Sleepiness Scale scores occurred at
baseline and all clinic visits. The Montreal Cognitive Assessment
scale was performed at baseline and maintenance. Dosing deci-
sions were made without knowledge of CYP2D6 metabolism
status.
Statistical analysis. Efficacy analyses were conducted in the
modified intent-to-treat (mITT) population, which included all
randomized patients who received study drug and had at least one
postbaseline AIMS assessment. The safety population included
patients who received at least one dose of study drug. The primary
analysis of change in AIMS score from baseline was conducted
with a linear mixed model for repeated measurements that
included fixed effects for treatment group, time point, treatment
group by time point interaction, and concomitant DRA use at
baseline. Baseline AIMS score was included as a covariate, and the
unstructured covariance model was used. The primary efficacy
analysis compared treatment groups at week 12 with the use of
a 2-sided test at the 5% significance level. Secondary endpoints,
defined as proportions of patients with treatment success (e.g.,
CGIC and PGIC), were compared between treatment groups
with the Pearson x2 test. Change in mCDQ-24 score from
baseline to week 12 was analyzed with an analysis of covariance
model with treatment group and concomitant DRA use at
baseline as factors, and with baseline mCDQ-24 score included as
a covariate.
Sample size. A 2-sided test at 5% significance was applied and
assumed an SD of 4.1 for the change from baseline to week 12 in
AIMS score. Approximately 90 patients provided 90% power to
detect a treatment difference of 2.8 units in the AIMS and 80%
power to detect a treatment difference of 2.4 units.
RESULTS Patient baseline characteristics and disposi-
tion. A total of 117 patients with TD were random-
ized to receive deutetrabenazine (n 5 58) or
placebo (n 5 59). A comparable proportion of
patients completed the study in both groups
(figure 1). Both groups had similar demographics and
Figure 1 Flow of study patients
After screening for eligibility, 117 patients were randomized to receive deutetrabenazine or placebo. A total of 89.7% and
88.1% of patients completed 12 weeks of treatment with deutetrabenazine or placebo, respectively.
Neurology 88 May 23, 2017 2005
baseline characteristics (table 1). Approximately 70%
of the population had an underlying diagnosis of
schizophrenia or schizoaffective disorder (table 1);
23.1% had bipolar disorder; and 25.6% had depres-
sion. The majority of patients (80.3%) were being
treated with a DRA at baseline and continued treat-
ment throughout the study.
Dose. At the end of the titration period, the mean
(SD) total daily dose was 38.8 (7.92) mg/d. The
mean [SD] dose remained stable until the end of
the treatment period (38.3 [7.97] mg/d).
Efficacy assessments. For the primary endpoint, deu-
tetrabenazine significantly reduced AIMS scores
from baseline to week 12 compared with placebo
(least-squares [LS] mean [standard error (SE)]:
23.0 [0.45] vs 21.6 [0.46], p 5 0.019; treatment
difference 21.4 [0.60], 95% confidence interval
[CI] 22.6 to 20.2) (figure 2). Improvement in
AIMS score was different between the deutetrabe-
nazine and placebo groups by week 4 with a treat-
ment effect of 21.5 (95% CI 22.6 to 20.4, p 5
0.007).
While the percentage of patients who achieved
treatment success on the CGIC (48.2% vs 40.4%)
and PGIC (42.9% vs 29.8%) favored deutetrabena-
zine, these differences were not statistically signifi-
cant. Similarly, deutetrabenazine-treated patients
had a greater LS mean [SE] reduction from baseline
to week 12 in the mCDQ-24 score than placebo
(211.1 [2.14] vs 28.3 [2.31]), but the difference
was not statistically significant.
Of the 113 patients in the mITT population, 97
patients (85.8%) had a centrally read AIMS score
$6 at both screening and baseline. Because this sub-
group represents the intended population for the
study, a post hoc analysis was performed on the
primary and key secondary endpoints. Similar to
the overall population, for the AIMS,
deutetrabenazine-treated patients had a greater
decrease in LS mean [SE] scores compared with pla-
cebo (3.4 [0.48] vs 1.9 [0.51], p5 0.027; treatment
difference 21.5 [0.67], 95% CI 22.8 to 20.2)
(figure 3). In the same subpopulation, the difference
in the percentage of patients who were classified as
a treatment success on the basis of the CGIC wid-
ened between the deutetrabenazine vs placebo arms
compared with the entire mITT cohort (25 [52.1%]
vs 17 [34.7%], p 5 0.084; treatment difference
17.4%, 95% CI 22.2% to 35.3%). The treatment
difference in this subpopulation was 17.4% com-
pared with 7.9% in the mITT cohort.
Compared with placebo, a greater percentage of
deutetrabenazine-treated patients in this subpopula-
tion had treatment success based on the PGIC
(45.8% vs 28.6%). Patients in the deutetrabenazine
group also had a greater LS mean [SE] reduction
from baseline to week 12 in the mCDQ-24 total
score (212.2 [2.21] vs 26.6 [2.39]). Similar to
the mITT population, these results were not statis-
tically significant.
Table 1 Patient baseline characteristics by treatment group
Deutetrabenazine
(n 5 58)
Placebo
(n 5 59)
All
(n 5 117)
Patient demographics
Age (SD), y 55.9 (9.8) 53.3 (10.6) 54.6 (10.3)
Female, n (%) 29 (50.0) 32 (54.2) 61 (52.1)
Male, n (%) 29 (50.0) 27 (45.8) 56 (47.9)
White, n (%) 37 (63.8) 44 (74.6) 81 (69.2)
Patient clinical characteristics
Weight (SD), kg 86.9 (24.1) 85.0 (21.0) 85.9 (22.5)
Duration of TD, mo 72.6 (81.7) 76.8 (82.1) 74.7 (81.5)
DRA use at baseline, n (%) 45 (77.6) 49 (83.1) 94 (80.3)
Most common antipsychotics
used at baseline, n (%)
Quetiapine 14 (24.1) 18 (30.5) 32 (27.4)
Risperidone 9 (15.5) 7 (11.9) 16 (13.7)
Olanzapine 8 (13.8) 5 (8.5) 13 (11.1)
Most common antidepressants
used at baseline, n (%)
Trazodone 9 (15.5) 10 (16.9) 19 (16.2)
Bupropion 5 (8.6) 6 (10.2) 11 (9.4)
Sertraline 6 (10.3) 4 (6.8) 10 (8.5)
Citalopram 5 (8.6) 5 (8.5) 10 (8.5)
Most common anxiolytics
used at baseline, n (%)
Hydroxyzine 5 (8.6) 6 (10.2) 11 (9.4)
Alprazolam 4 (6.9) 4 (6.8) 8 (6.8)
Buspirone 1 (1.7) 2 (3.4) 3 (2.6)
Diazepam 1 (1.7) 2 (3.4) 3 (2.6)
Psychiatric disorder comorbidity,
n (%)
57 (98.3) 58 (98.3) 115 (98.3)
Schizophreniaa 29 (50.0) 29 (49.2) 58 (49.6)
Schizoaffective disorderb 11 (19.0) 11 (18.6) 22 (18.8)
Bipolar disorderc 12 (20.7) 15 (25.4) 27 (23.1)
Depression 17 (29.3) 13 (22.0) 30 (25.6)
AIMS score, items 1–7 (SD) 9.6 (4.1) 9.6 (3.8) 9.6 (3.9)
AIMS score ‡6, n (%) 48 (82.8) 49 (83.1) 97 (82.9)
Total mCDQ-24 score (SD) 38.4 (20.4) 39.7 (18.2) 39.1 (19.3)
Total UPDRS score (SD) 9.5 (9.8) 10.2 (8.7) 9.9 (9.2)
Abbreviations: AIMS 5 Abnormal Involuntary Movement Scale (maximum total score 5 28);
DRA 5 dopamine receptor agonist; mCDQ-24 5 Modified Craniocervical Dystonia Ques-
tionnaire (maximum total score 5 96); TD 5 tardive dyskinesia; UPDRS 5 Unified Parkin-
son’s Disease Rating Scale motor assessment (maximum total score 5 56).
a Includes schizophrenia, schizophrenia paranoid type, and schizophrenia residual type.
b Includes schizoaffective disorder and schizoaffective disorder depressive type.
c Includes bipolar disorder, bipolar I disorder, and bipolar II disorder.
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Safety assessments. Patients from the deutetrabenazine
and placebo groups reported similar rates of AEs. The
most common AEs (.4% of patients in either group)
are presented in table 2.
Treatment-related AEs were reported in 48.3% of
the deutetrabenazine group compared with 35.6% of
the placebo group. Notably, the incidence of several
AEs of interest in the deutetrabenazine group, such
as depression/depressed mood and suicidal ideation,
was similar to or lower than for placebo.
Serious AEs were reported by 3 patients (5.2%) in
the deutetrabenazine group and 5 patients (8.5%)
receiving placebo. Serious AEs in the deutetrabena-
zine group included community-acquired pneumo-
nia, substance-induced manic episode, and
exacerbation of schizophrenia (n 5 1 for each). Seri-
ous AEs in the placebo group included accidental
heroin overdose, jaw fracture secondary to falling,
jaw infection, pneumonia, and laryngeal hypertrophy
(n 5 1 for each). None were considered treatment
related. There were no deaths during the study.
For the deutetrabenazine and placebo groups,
there were relatively low rates of dose reductions, sus-
pensions, and study withdrawals due to AEs, as pre-
sented in table 2.
Similar incidences of psychiatric AEs were observed
in the overall deutetrabenazine group (20.7%) and in
the cohort of patients taking deutetrabenazine with
antipsychotics (19.6%), antidepressants (26.5%), or
anxiolytics (23.1%). Deutetrabenazine treatment with
concomitant antidepressants and anxiolytics was asso-
ciated with similar rates of psychiatric AEs compared
with placebo; however, there were more psychiatric
AEs in patients treated with deutetrabenazine with
antipsychotics compared with placebo (19.6% vs
9.8%). Nonetheless, the incidence of depressed mood,
Figure 2 Mean change in AIMS score
AIMS score was assessed over 12 weeks by central video rating in the mITT population
based on the linear mixed model for repeated measurements. The mean change in AIMS
score from baseline at weeks 2, 4, 6, 9, and 12 is depicted. Error bars represent standard
error. AIMS 5 Abnormal Involuntary Movement Scale; mITT 5 modified intent to treat.
*p 5 0.007. **p 5 0.019.
Figure 3 Analysis of treatment effect for efficacy parameters
(A) Treatment difference (deutetrabenazine–placebo) of the LS mean change in AIMS score. (B) Proportion of patients who
experience treatment success on the CGIC. Error bars for AIMS are standard error. AIMS 5 Abnormal Involuntary Move-
ment Scale; CGIC 5 Clinical Global Impression of change; LS 5 least squares.
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depression, and suicidal ideation remained low and was
similar to that of the overall deutetrabenazine group in
patients receiving concomitant antidepressants.
Small reductions in parkinsonism severity, as
measured by the Unified Parkinson’s Disease Rat-
ing Scale motor assessment, were observed from
baseline to week 12 in the deutetrabenazine (mean
[SD] change 20.9 [8.09]) and placebo (23.8
[7.87]) arms. In addition, at week 12, there were
no safety signals detected on the Barnes Akathisia
Rating Scale, HADS-Anxiety, HADS-Depression,
Epworth Sleepiness Scale, or Montreal Cognitive
Assessment. No deutetrabenazine-treated patient
reported suicidal ideation or behavior on the
Columbia Suicide Severity Rating Scale, whereas
3 patients (5.2%) and 1 patient (1.7) in the placebo
group reported suicidal ideation or behavior,
respectively.
Finally, there were no meaningful differences in
the QTcF interval prolongation between groups
(p 5 0.153). One placebo-treated patient exceeded
a QTcF interval of 500 milliseconds.
DISCUSSION This study demonstrated that deute-
trabenazine is efficacious for the treatment of abnor-
mal movements in patients with TD, with
a favorable safety and tolerability profile that enables
the continued use of DRAs and antidepressants for
the management of chronic psychiatric conditions.
Almost all patients (98.3%) enrolled in Aim to
Reduce Movements in Tardive Dyskinesia (ARM-
TD) had an underlying psychiatric comorbidity for
which they were receiving concomitant medications,
making these results especially relevant to clinical
practice for clinicians managing similar patients in
a real-world setting.
In general, deutetrabenazine was well tolerated,
as supported by the high study completion rate
and infrequent dose reductions, dose suspensions,
or withdrawals. These results are of particular
importance because antipsychotic discontinuation
or dose reduction is often not possible for patients
with TD because of the high risk of psychotic exac-
erbation.9 Moreover, deutetrabenazine did not result
in reports of depression or suicidal ideation and was
associated with low rates of psychiatric AEs, includ-
ing anxiety.
Because of possible differences between on-site
and centralized video ratings of TD, natural varia-
tion in the severity of dyskinesia, and potential dif-
ferences among patients’ subjective feelings (e.g.,
more nervous during the initial video) at screening
vs baseline, 20 enrolled patients had AIMS scores
,6 as assessed by a central video rater at baseline,
leaving 97 patients (85.8% of the mITT popula-
tion) with central video AIMS scores $6 at both
screening and baseline. Because this population is
consistent with the intended study population, the
key efficacy endpoints were assessed for this group
to inform future study design. As with the mITT
population, a significant improvement in AIMS
score at week 12 was also observed with deutetra-
benazine compared with placebo for this popula-
tion. Deutetrabenazine provided greater clinical
benefit, as evidenced by numeric improvement on
CGIC, in patients with a central video AIMS score
$6 at screening and baseline, suggesting that pa-
tients with more severe TD may exhibit better clin-
ical response.
The chronic, disabling nature of TD21,22 high-
lights the need for an effective treatment. The signif-
icant improvement observed in AIMS score was not
fully reflected on CGIC and PGIC outcomes. This
may be due to variable symptom appreciation by the
clinician and the patient. Most patients in this trial
were recruited and evaluated by psychiatrist investi-
gators who may be less familiar with the motor nu-
ances of TD compared with the management of
behavioral disorders. Psychiatrists have not been
Table 2 Patients who reported adverse events (AEs) in each treatment group
Deutetrabenazine
(n 5 58), n (%)
Placebo
(n 5 59), n (%)
Any AE 41 (70.7) 36 (61.0)
Serious AE 3 (5.2) 5 (8.5)
Treatment-related AEs 28 (48.3) 21 (35.6)
AE leading to dose reduction 6 (10.3) 3 (5.1)
AE leading to dose suspension 3 (5.2) 5 (8.5)
AE leading to discontinuation 1 (1.7) 2 (3.4)
AEs of interest
Depressed mood 1 (1.7) 0 (0.0)
Depression 0 (0.0) 1 (1.7)
Suicidal ideation 0 (0.0) 1 (1.7)
AEs occurring in >4% of patients in either
treatment group
Somnolence 8 (13.8) 6 (10.2)
Fatigue 4 (6.9) 5. (8.5)
Insomnia 4 (6.9) 1 (1.7)
Headache 3 (5.2) 6 (10.2)
Diarrhea 3 (5.2) 3 (5.1)
Akathisia 3 (5.2) 0 (0.0)
Anxiety 2 (3.4) 4 (6.8)
Dizziness 2 (3.4) 3 (5.1)
Dry mouth 2 (3.4) 6 (10.2)
Upper respiratory tract infection 2 (3.4) 3 (5.1)
Rash 1 (1.7) 3 (5.1)
Vomiting 1 (1.7) 3 (5.1)
Deaths 0 0
2008 Neurology 88 May 23, 2017
consistently exposed to rigorous training on the scales
used in the study. In addition, the dynamic nature of
TD itself may limit the ability of these scales to fully
capture meaningful change in involuntary move-
ments. It is possible that tolerability issues could have
dampened the CGIC and PGIC treatment effects.
We believe this is unlikely because the active drug
was very well tolerated.
There was, surprisingly, a notable placebo
response among patients on the AIMS rating, which
could have also affected the CGIC and PGIC ratings,
despite the centralized video assessment. This may be
attributed to the patients’ perception or expectation
of improvement due to the titration design and fre-
quent clinic visits, compounded by the variability
over time of TD, which is not often consistently
manifested and is very susceptible to external factors
such as stress, time of day, and intake of psychotropic
medications. In addition, the positive findings of
a related study in HD (First Time Use of SD-809
in Huntington Disease [First-HD]) were publically
announced while this study was being conducted.19
The placebo effect on AIMS scores was less likely
from the central raters because they were blinded to
clinical information, concordance with another cen-
tral rater was required, and all videos of each patient
were viewed in the same sitting. Using central video
raters reduces the potential for interrater variability23
or visit-specific factors, leading to more standardized
measures.
There are few available treatment options for
involuntary movements related to TD. The American
Academy of Neurology guidelines do not conclusively
recommend off-label use of tetrabenazine for the
treatment of TD symptoms (Class III, Level C, Level
U).8 This study provides Class I evidence that deute-
trabenazine may serve as an efficacious and well-
tolerated treatment for abnormal movements in
TD, particularly in patients in whom disruption of
treatment for underlying psychiatric conditions may
not be an option.
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